SynthesisFrontiers in oncology2025
Chemotherapy cardiotoxicity research in cancer patients: a bibliometric and visual analysis (1994-2024).
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Phytochemicals from Agro-Industrial By-Products for Breast Cancer Prevention and Therapy: Molecular Mechanisms and Circular Bioeconomy Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Wearable-Based Assessment of Cardiac Recovery After a Modified Bruce Test in Women with Breast Cancer: Role of Physical Activity and Treatment Duration.Sensors (Basel, Switzerland) · 2026Article
- Evaluation of metformin's effect on 5-fluorouracil-induced cardiotoxicity through cellular protection.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Traditional Chinese medicine-induced cardiac adverse reactions: a critical review of current evidence, knowledge gaps, and pharmacovigilance strategies.Frontiers in pharmacology · 2026Review
- Cardiac Surgery and Postoperative Atrial Fibrillation: The Role of Cancer.Medicina (Kaunas, Lithuania) · 2025Review
- Design and Optimization of Spiro-Isatin-Thiazolidinone Hybrids with Promising Anticancer Activity.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent advancements in medical technology have significantly boosted the survival rates of cancer patients. The potential toxicities that cancer treatments may induce in other areas of the human body have garnered increasing attention. Chemotherapy, a pivotal component of anticancer therapy, heightens the risk of cardiac damage and contributes to various cardiovascular complications. To comprehensively assess the research landscape concerning chemotherapy-induced cardiotoxicity in cancer patients, this study conducted a visual analysis of pertinent articles utilizing bibliometric tools. Method: We used CiteSpace, VOSviewer, to analyze the temporal and spatial distribution, disciplinary categories, authorship, references, subject terms, and keywords of 4460 articles retrieved from the Web of Science core collection from 1994 to January 21, 2024. Results: Contributions to this field emanated from 100 countries/regions and 4,343 research institutions, with the United States, China, and Italy emerging as the most prolific contributors in terms of publication volume. The Journal of Clinical Oncology emerged as the primary journal in terms of publications and co-citations within this domain, with Bonnie Ky identified as the most prolific author. Common keywords included breast cancer, doxorubicin, heart failure, trial, adjuvant chemotherapy, paclitaxel, and risk. Terms such as echocardiography, nanoparticles, mechanisms, prevention, society, oxidative stress, inflammation, consensus, and global longitudinal strain delineated the current research frontier in this field. Additionally, the study provided a detailed examination of the fundamental aspects of research in this domain. Presently, key research focuses in this area include elucidating the mechanisms of chemotherapy-induced cardiotoxicity, monitoring and evaluating such cardiotoxicity, and developing strategies for its prevention and treatment. Conclusion: This study provides a comprehensive overview of chemotherapy-induced cardiotoxicity research from 1994 to 2024. Future research should prioritize personalized risk assessment and interdisciplinary collaboration to meet the clinical needs of the cardiovascular oncology field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.